TITLE

Effects of Intracellular and Extracellular Calcium Blockers on the Pulmonary Vascular Responses to PGF2a and U46619

AUTHOR(S)
Santoian, Edward C.; Angerio, Allan D.; Fitzpatrick, Thomas M.; Rose, John C.; Ramwell, Peter W.; Kot, Peter A.
PUB. DATE
January 1987
SOURCE
Angiology;Jan1987 Part 1, Vol. 38 Issue 1, p51
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In this study, TMB-8, an intracellular calcium antagonist, and verapamil, an extracellular calcium antagonist, were used simultaneously to elucidate the role of calcium in the pulmonary vasopressor response induced by PGF2α and U46619. The pulmonary vasoconstrictor action of these two agonists was evaluated in the canine isolated lung lobe preparation. Lobar arterial pressure was constantly monitored and changes in arterial pressure were recorded as a percentage from baseline. Control responses to PGF2α (42.0±8.2%) and U46619 (47.2±7.0%) were obtained prior to the administration of TMB-8 and verapamil. After administration of TMB-8 and verapamil, the PGF2α (7.4±3.1%) and U46619 (28.8±6.2%) responses were significantly attenuated. We conclude that the PGF2α pressor response is dependent on a TMB-8-sensitive intracellular calcium pool and a verapamil-sensitive slow-channel calcium influx. In contrast, the degree of attenuation of the U46619 response was similar to the vasopressor response in the presence of verapamil alone, as described previously. This indicates a direct dependence on extracellular calcium. An additional source of calcium insensitive to verapamil and TMB-8 may also be activated and contribute to the pulmonary vasoconstrictor action. These results suggest that each agonist possesses a mechanism of action distinctly different from the other.
ACCESSION #
16478625

 

Related Articles

  • COER Verapamil Is Ineffective in Preventing CV Disease. Wellbery, Caroline // American Family Physician;12/1/2003, Vol. 68 Issue 11, p2262 

    Presents an abstract of the study "Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial," by H.R. Black et al., from the April 23/30, 2003 issue of the "Journal of the American Medical Association."

  • A new in vitro method of decongestant assay of nasal mucosa: A preliminary report. Hsing-Won Wang; Chuan-Hsiang Kao; Yueng-Hsiang Chu // American Journal of Rhinology;Jan/Feb2006, Vol. 20 Issue 1, p43 

    Background: The calculation of cell planar surface area, successfully used for glomerular mesangial cell-altered contractility, also is a reasonable methodology to assess nasal mucosal contractility. A simple technique that works particularly well with vasoconstriction-inducing agents has been...

  • verapamil hydrochloride.  // Royal Society of Medicine: Medicines;2002, p561 

    This article presents information on verapamil hydrochloride drug. The drug is a calcium-channel blocker which is used as an anti-angina drug in the prevention and treatment of attacks. It can also be used as an anti-arrhythmic to correct heart irregularities and as an antihypertensive....

  • Effects of Diltiazem on Occupational Raynaud's Syndrome (Vibration Disease). Matoba, Tsunetaka; Chiba, Michio // Angiology;Dec1985, Vol. 36 Issue 12, p850 

    An open trial on the therapeutic effect of diltiazem, a calcium antagonist, was conducted on occupational Raynaud's syndrome (vibration disease). Seventeen men with vibration disease were studied. The mean age was 54 years. No patient had cardiovascular disease. Primary and secondary cases of...

  • nondihydropyridine calcium antagonist.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1594 

    An encyclopedia entry for "nondihydropyridine calcium antagonist," is presented, which refers to a calcium blocker like verapamil and diltiazem.

  • Calcium antagonists: Safe after all. Pinkowish, Mary Desmond // Patient Care;12/15/1998, Vol. 32 Issue 20, p188 

    Reports on the study that examined the association of between calcium channel blockers and high mortality in patients with hypertension. Agents and classes of calcium channel blockers.

  • One more drug in the battle against hypertension. Cerrato, Paul L. // RN;Jun96, Vol. 59 Issue 6, p69 

    Reports on the development of a new calcium channel blocker called nisoldipine (Sular) for the treatment of hypertension. Lowering of blood pressure through the dilation of arterioles; Recommended dose; Special precautions when ingesting the drug.

  • Osmoregulatory reactions of frog erythrocytes under conditions of activation and blockade of Ca-channels. Skorkina, M. // Journal of Evolutionary Biochemistry & Physiology;Mar2012, Vol. 48 Issue 2, p147 

    The kinetics of cell osmoregulatory reactions under conditions of activation and blockade of Ca-channels was studied on a model of frog polyfunctional nucleated erythrocytes. Both activation and blockade of Ca-channels has been established to promote swelling of nuclei and an increase of the...

  • Characterization of basolateral-to-apical transepithelial transport of cadmium in intestinal TC7 cell monolayers. Carrière, Pascale; Mantha, Marc; Champagne-Paradis, Sophie; Jumarie, Catherine // BioMetals;Oct2011, Vol. 24 Issue 5, p857 

    Cadmium (Cd) is a toxic metal with an extremely long half-life in humans. The intestinal absorption of Cd has been extensively studied but the role the intestinal epithelium may play in metal excretion has never been considered. The basolateral (BL)-to-apical (AP) transepithelial transport of Cd...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics